Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term ...

CagriSema is a fixed-dose combination of a long-acting amylin ... Novo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote Following the news, shares of Novo Nordisk’s archrival in ...

Protean Small Cap beat its benchmark in December. It returned 0.3%, while the index retracted by -0.1%. Click here to read ...

Meanwhile, people enrolled in the study who were given either semaglutide or cagrilintide alone were more likely to tolerate that higher dose. Cagrisema is one of a wave of treatments in ...

While CagriSema matches the competition in overall efficacy, challenges in tolerability at the highest dose and variability in patient adherence have emerged as critical areas of focus.

Meanwhile, people enrolled in the study who were given either semaglutide or cagrilintide alone were more likely to tolerate that higher dose. CagriSema is one of a wave of treatments in ...

A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss targeted by executives, prompting investors to wipe 19% off the value ...